A Multicenter, Open-label, Randomized, 2-arm, Phase II Trial of Pharmacodynamics, Pharmacokinetics and Safety of Two Dose Regimens of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chronic Hepatitis C Genotype 2 and 3 Patients Who Have Previously Failed Interferon Therapy or Are Intolerant or Unable to Take Interferon.
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2016
Price : $35 *
At a glance
- Drugs Alisporivir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Pharmacodynamics
- Acronyms ALtitude II
- Sponsors Debiopharm; Novartis
- 04 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Apr 2015 Planned End Date changed from 1 Oct 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
- 25 Apr 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.